Prof Sam Janes

Dr Sam JanesTel: 020 3447 9005
Fax: 020 3447 9476

University College Hospital

Lung cancer, Medical specialties, Respiratory Medicine

Professional background

Dr Janes qualified in 1992 gaining a BSc and MBBS. He trained in respiratory medicine at several hospitals including the Hammersmith, Harefield and St Mary’s Hospitals and completed an MSc (Distinction) in Respiratory Medicine in 1999 at the Brompton Hospital. He gained his CCST in Respiratory and General Medicine in 2004. He won a MRC Training Fellowship and worked in the CRUK Lincoln’s Inn Fields Institute with Fiona Watt working on integrin adhesion molecules and cancer cell survival leading to his PhD in 2004. He then worked as a post-doctoral fellow at the same institute before moving to University College London. At UCL he won an MRC Clinician Scientist Fellowship and now leads a group interested in the pathogenesis of lung disease including cancer formation and its treatment with new biological and cellular therapies within the Centre for Respiratory Research. He has a particular interest in using stem cells as a cellular vector for gene therapy in cancers.

Research interests

Dr Janes runs the UCLH lung cancer team and has a clinic (SJ41A) on Monday afternoons. He has developed a new endobronchial ultrasound service and performs all the invasive bronchoscopic techniques. He is running several clinical trials aiming to improve the patient journey of diagnosis and staging of lung cancers. These trials include a number of innovative techniques. He works as a consultant for the NHS in respiratory and general medicine with a particular interest in lung cancer, mesothelioma, bronchoscopy and early lung cancer detection.


He has published 25 papers surrounding lung cancer and sits on the British Thoracic Society and British Lung Foundation scientific committees. He edited the European Monograph on lung cancer in 2009.

Selected publications:

Navani N, Spiro SG, Janes SM.
Mediastinal staging of NSCLC with endoscopic and endobronchial ultrasound.
Nat Rev Clin Oncol. 2009 May;6(5):278-86.

Aguilar S, Scotton C, McNulty K, Nye E, Stamp G, Laurent G, Bonnet D and Janes SM
Bone Marrow Stem Cells Expressing Keratinocyte Growth Factor via an Inducible Lentivirus Protects against Bleomycin-induced Pulmonary Fibrosis.
PLoS One. 2009 Nov 24;4(11):e8013

Loebinger MR, Kyrtatos PG, Turmaine M, Price AN, Pankhurst Q, Lythgoe M and Janes SM.
Magnetic resonance imaging of mesenchymal stem cells homing to pulmonary metastases using biocompatible magnetic nanoparticles.
Cancer Res. 2009 Dec 1;69(23):8862-7. Epub 2009 Nov 17.

Loebinger MR, Eddaoudi A, Davies D, Janes SM.
Mesenchymal stem cell delivery of TRAIL can eliminate metastatic cancer.
Cancer Res. 2009 May 15;69(10):4134-42.

Loebinger MR, Sage EK, Janes SM.
Mesenchymal stem cells as vectors for lung disease.
Proc Am Thorac Soc. 2008 Aug 15;5(6):711-6.

Spiro SG, Douse J, Read C, Janes S.
Complications of lung cancer treatment.
Semin Respir Crit Care Med. 2008 Jun;29(3):302-17.

Read C, Janes S, George J, Spiro S.
Early lung cancer: screening and detection.
Prim Care Respir J. 2006 Dec;15(6):332-6.

Janes SM, Ofstad TA, Campbell DH, Eddaoudi A, Warnes G, Davies D, Watt FM.
PI3-kinase-dependent activation of apoptotic machinery occurs on commitment of
epidermal keratinocytes to terminal differentiation.
Cell Res. 2009 Mar;19(3):328-39.

Loebinger MR, Giangreco A, Groot KR, Prichard L, Allen K, Simpson C, Bazley L,
Navani N, Tibrewal S, Davies D, Janes SM.
Squamous cell cancers contain a side population of stem-like cells that are made chemosensitive by ABC transporter blockade.
Br J Cancer. 2008 Jan 29;98(2):380-7.

Janes SM, Rahman NM, Davies RJ, Lee YC.
Catheter-tract metastases associated with chronic indwelling pleural catheters. Chest. 2007 Apr;131(4):1232-4.

Aguilar S, Nye E, Chan J, Loebinger M, Spencer-Dene B, Fisk N, Stamp G,
Bonnet D, Janes SM.
Murine but not human mesenchymal stem cells generate osteosarcoma-like lesions in the lung.
Stem Cells. 2007 Jun;25(6):1586-94.
Janes SM, Watt FM.
New roles for integrins in squamous-cell carcinoma.
Nat Rev Cancer. 2006 Mar;6(3):175-83.

Griffiths MJ, Bonnet D, Janes SM.
Stem cells of the alveolar epithelium.
Lancet. 2005 Jul 16-22;366(9481):249-60.

Albera C, Polak JM, Janes S, Griffiths MJ, Alison MR, Wright NA,
Navaratnarasah S, Poulsom R, Jeffery R, Fisher C, Burke M, Bishop AE.
Repopulation of human pulmonary epithelium by bone marrow cells: a potential
means to promote repair.
Tissue Eng. 2005 Jul-Aug;11(7-8):1115-21.

Janes SM, Ofstad TA, Campbell DH, Watt FM, Prowse DM.
Transient activation of FOXN1 in keratinocytes induces a transcriptional programme that promotes terminal differentiation: contrasting roles of FOXN1 and Akt.
J Cell Sci. 2004 Aug 15;117(Pt 18):4157-68.

Janes SM, Watt FM.
Switch from alphavbeta5 to alphavbeta6 integrin expression protects squamous cell carcinomas from anoikis.
J Cell Biol. 2004 Aug 2;166(3):419-31.

GMC/GDC number: 3581122